Abivax Statistics

Total Valuation

Abivax has a market cap or net worth of $780.18 million. The enterprise value is $576.85 million.

Market Cap	780.18M
Enterprise Value	576.85M

Important Dates

The next estimated earnings date is Monday, September 9, 2024, before market open.

Earnings Date	Sep 9, 2024
Ex-Dividend Date	n/a

Share Statistics

Abivax has 62.92 million shares outstanding.

Shares Outstanding	62.92M
Shares Change (YoY)	n/a
Shares Change (QoQ)	+19.95%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	1.76%
Float	22.81M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	151.95
Forward PS	n/a
PB Ratio	3.65
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	112.35
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 4.08, with a Debt / Equity ratio of 0.38.

Current Ratio	4.08
Quick Ratio	n/a
Debt / Equity	0.38
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-4.30

Financial Efficiency

Return on equity (ROE) is -145.40% and return on invested capital (ROIC) is -47.09%.

Return on Equity (ROE)	-145.40%
Return on Assets (ROA)	-73.40%
Return on Capital (ROIC)	-47.09%
Revenue Per Employee	$84,171
Profits Per Employee	-$2.69M
Employee Count	61
Asset Turnover	0.02
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

Beta (5Y)	1.37
52-Week Price Change	n/a
50-Day Moving Average	13.60
200-Day Moving Average	n/a
Relative Strength Index (RSI)	35.98
Average Volume (20 Days)	71,657

Short Selling Information

Short Interest	91,323
Short Previous Month	107,921
Short % of Shares Out	0.15%
Short % of Float	0.40%
Short Ratio (days to cover)	0.63

Income Statement

In the last 12 months, Abivax had revenue of $5.13 million and -$164.16 million in losses. Loss per share was -$3.74.

Revenue	5.13M
Gross Profit	5.03M
Operating Income	-138.75M
Pretax Income	-160.93M
Net Income	-164.16M
EBITDA	-129.79M
EBIT	-130.56M
Loss Per Share	-$3.74

Full Income Statement

Balance Sheet

The company has $284.44 million in cash and $81.11 million in debt, giving a net cash position of $203.32 million or $3.23 per share.

Cash & Cash Equivalents	284.44M
Total Debt	81.11M
Net Cash	203.32M
Net Cash Per Share	$3.23
Equity (Book Value)	213.51M
Book Value Per Share	3.39
Working Capital	235.20M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$105.80 million and capital expenditures -$288,654, giving a free cash flow of -$106.09 million.

Operating Cash Flow	-105.80M
Capital Expenditures	-288,654
Free Cash Flow	-106.09M
FCF Per Share	-$2.46

Full Cash Flow Statement

Margins

Gross margin is 98.03%, with operating and profit margins of -2,702.25% and -3,197.14%.

Gross Margin	98.03%
Operating Margin	-2,702.25%
Pretax Margin	-3,134.27%
Profit Margin	-3,197.14%
EBITDA Margin	-2,527.91%
EBIT Margin	-2,542.91%
FCF Margin	-2,066.21%

Dividends & Yields

Abivax does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-21.04%
FCF Yield	-13.60%

Analyst Forecast

The average price target for Abivax is $34.20, which is 175.81% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$34.20
Price Target Difference	175.81%
Analyst Consensus	Strong Buy
Analyst Count	5
Revenue Growth Forecast (5Y)	148.79%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Abivax has an Altman Z-Score of 1.67 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.67
Piotroski F-Score	1